Cited 26 times in
Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 금기창 | - |
dc.contributor.author | 김세헌 | - |
dc.contributor.author | 김주항 | - |
dc.contributor.author | 신상준 | - |
dc.contributor.author | 조병철 | - |
dc.contributor.author | 최은창 | - |
dc.contributor.author | 최혜진 | - |
dc.date.accessioned | 2015-04-24T17:02:36Z | - |
dc.date.available | 2015-04-24T17:02:36Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/104651 | - |
dc.description.abstract | BACKGROUND: The objective of the study was to investigate the efficacy and tolerability of weekly docetaxel in patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). METHODS: Patients fulfilling the following criteria were enrolled: histologically confirmed SCCHN; documented progressive disease (PD) after platinum-based treatment; Eastern Cooperative Oncology Group (ECOG) 0-2; measurable disease; not candidates for local therapy. Docetaxel (35 mg/m(2)) was administered for 3 weeks, every 4 weeks for a maximum of 6 cycles. RESULTS: A total of 23 patients were treated. All patients were assessable for toxicity and response. The overall response rate was 13.0% (3/23) and disease control rate was 34.7% (8/23). Median progression-free and overall survival (OS) was 9 (95% CI, 7.6-10.4 weeks) and 29 weeks (95% CI, 10.8-47.1 weeks), respectively. Most common hematological toxicities were grade 1-2 anemia (6/23, 26.1%) and nonhematological toxicities were mild and manageable. There was no treatment-related death. CONCLUSION: Weekly docetaxel regimen had good clinical activity with an acceptable toxicity in patients with platinum-refractory SCCHN | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 27~32 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anemia/chemically induced | - |
dc.subject.MESH | Antineoplastic Agents/adverse effects | - |
dc.subject.MESH | Antineoplastic Agents/therapeutic use* | - |
dc.subject.MESH | Carcinoma, Squamous Cell/drug therapy* | - |
dc.subject.MESH | Carcinoma, Squamous Cell/mortality | - |
dc.subject.MESH | Disease-Free Survival | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Head and Neck Neoplasms/drug therapy* | - |
dc.subject.MESH | Head and Neck Neoplasms/mortality | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Neoplasm Metastasis | - |
dc.subject.MESH | Neoplasm Recurrence, Local | - |
dc.subject.MESH | Survival Rate | - |
dc.subject.MESH | Taxoids/adverse effects | - |
dc.subject.MESH | Taxoids/therapeutic use* | - |
dc.title | Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Otorhinolaryngology (이비인후과학) | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Ki Chang Keum | - |
dc.contributor.googleauthor | Sang Joon Shin | - |
dc.contributor.googleauthor | Hye Jin Choi | - |
dc.contributor.googleauthor | Young Joo Lee | - |
dc.contributor.googleauthor | Se Hun Kim | - |
dc.contributor.googleauthor | Eun Chang Choi | - |
dc.contributor.googleauthor | Joo Hang Kim | - |
dc.identifier.doi | 10.1007/s00280-009-0999-4 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00272 | - |
dc.contributor.localId | A00605 | - |
dc.contributor.localId | A00945 | - |
dc.contributor.localId | A02105 | - |
dc.contributor.localId | A03822 | - |
dc.contributor.localId | A04161 | - |
dc.contributor.localId | A04219 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 19381630 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-009-0999-4 | - |
dc.subject.keyword | Docetaxel | - |
dc.subject.keyword | Head and neck | - |
dc.subject.keyword | Squamous cell carcinoma | - |
dc.subject.keyword | Chemotherapy | - |
dc.subject.keyword | Platinum-refractory | - |
dc.contributor.alternativeName | Keum, Ki Chang | - |
dc.contributor.alternativeName | Kim, Se Heon | - |
dc.contributor.alternativeName | Kim, Joo Hang | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.alternativeName | Choi, Eun Chang | - |
dc.contributor.alternativeName | Choi, Hye Jin | - |
dc.contributor.affiliatedAuthor | Keum, Ki Chang | - |
dc.contributor.affiliatedAuthor | Kim, Se Heon | - |
dc.contributor.affiliatedAuthor | Kim, Joo Hang | - |
dc.contributor.affiliatedAuthor | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | Choi, Eun Chang | - |
dc.contributor.affiliatedAuthor | Choi, Hye Jin | - |
dc.citation.volume | 65 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 27 | - |
dc.citation.endPage | 32 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.65(1) : 27-32, 2009 | - |
dc.identifier.rimsid | 52834 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.